$510.36▾ 0.73%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-197.72MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+71.2%year over year
Decelerating
Still growing fast, but the pace has been easing.
Leverage
Lowdebt to assets
Healthy
A modest, well-covered debt load.
More coming: dilution / share-count creep.
✦ The read
Madrigal Pharmaceuticals, Inc. is pre-profit. It is still burning cash while pre-profit. Still growing fast, but the pace has been easing. A modest, well-covered debt load.
Key numbers
Valuation
EPS (TTM)$-12.85
TTM (trailing 12 months, through fiscal Q2 FY2026)
Profitability
Net margin-25.3%
TTM (trailing 12 months, through fiscal Q2 FY2026)
Size
Revenue (TTM)$1.28B
TTM (trailing 12 months, through fiscal Q2 FY2026)
Recent news
Signals and key numbers are from the fiscal Q2 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.